Yang Y, Peng H, Wang J, Li F
Exp Hematol Oncol. 2024; 13(1):110.
PMID: 39521987
PMC: 11549815.
DOI: 10.1186/s40164-024-00573-9.
Mingot-Castellano M, Reguera-Ortega J, Zafra Torres D, Hernani R, Lopez-Godino O, Guerreiro M
J Clin Med. 2024; 13(17).
PMID: 39274330
PMC: 11396136.
DOI: 10.3390/jcm13175117.
Cordeiro A, Durisek G, Batista M, Schmidt J, de Lima M, Bezerra E
Front Oncol. 2024; 14:1404351.
PMID: 38919524
PMC: 11196778.
DOI: 10.3389/fonc.2024.1404351.
Perna F, Parekh S, Diorio C, Smith M, Subklewe M, Mehta R
Blood Adv. 2024; 8(16):4348-4358.
PMID: 38861351
PMC: 11375260.
DOI: 10.1182/bloodadvances.2024013044.
Brudno J, Kochenderfer J
Nat Rev Clin Oncol. 2024; 21(7):501-521.
PMID: 38769449
PMC: 11529341.
DOI: 10.1038/s41571-024-00903-0.
Cryo-EM structure of the extracellular domain of murine Thrombopoietin Receptor in complex with Thrombopoietin.
Sarson-Lawrence K, Hardy J, Iaria J, Stockwell D, Behrens K, Saiyed T
Nat Commun. 2024; 15(1):1135.
PMID: 38326297
PMC: 10850085.
DOI: 10.1038/s41467-024-45356-2.
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).
Vic S, Thibert J, Bachy E, Cartron G, Gastinne T, Morschhauser F
Blood Adv. 2024; 8(6):1573-1585.
PMID: 38181767
PMC: 10982963.
DOI: 10.1182/bloodadvances.2023011727.
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K, Wang Y, Hansen D, Iacoboni G, Bachy E, Bansal R
Blood Adv. 2024; 8(8):1857-1868.
PMID: 38181508
PMC: 11007437.
DOI: 10.1182/bloodadvances.2023011767.
Celebrating a year of cancer research in Blood Advances.
Bollard C, Weyrich A
Blood Adv. 2023; 7(24):7621-7623.
PMID: 38147360
PMC: 10790076.
DOI: 10.1182/bloodadvances.2023011867.
Recognizing, defining, and managing CAR-T hematologic toxicities.
Rejeski K, Subklewe M, Locke F
Hematology Am Soc Hematol Educ Program. 2023; 2023(1):198-208.
PMID: 38066881
PMC: 10727074.
DOI: 10.1182/hematology.2023000472.
[CAR-T cell therapy-related long-term cytopenias].
Li A, Feng R
Zhonghua Xue Ye Xue Za Zhi. 2023; 44(10):870-875.
PMID: 38049346
PMC: 10694071.
DOI: 10.3760/cma.j.issn.0253-2727.2023.10.018.
Prolonged haematologic toxicity in CAR-T-cell therapy: A review.
Liu Q, Hu T, Li H, Shen Y, Wu D, Ye B
J Cell Mol Med. 2023; 27(23):3662-3671.
PMID: 37702530
PMC: 10718150.
DOI: 10.1111/jcmm.17930.
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.
Epperly R, Giordani V, Mikkilineni L, Shah N
Hematol Oncol Clin North Am. 2023; 37(6):1169-1188.
PMID: 37349152
PMC: 10592597.
DOI: 10.1016/j.hoc.2023.05.010.
Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?.
Sun T, Li D, Huang L, Zhu X
Front Immunol. 2023; 14:1141779.
PMID: 37223096
PMC: 10200893.
DOI: 10.3389/fimmu.2023.1141779.
How I treat cytopenias after CAR T-cell therapy.
Jain T, Olson T, Locke F
Blood. 2023; 141(20):2460-2469.
PMID: 36800563
PMC: 10646792.
DOI: 10.1182/blood.2022017415.
